Apatoff | Peters Advises Biotechnology Company on Major Research Agreement
 
Rockville, MD. Cangen Biotechnologies, Inc., a Bethesda, Maryland-based biotechnology company, announced on Friday, January 6th the expansion of its existing collaborative research agreement with Olympus Corporation of Tokyo, Japan to accelerate the commercialization of Cangen’s technology for the early detection of lung cancer. Cangen’s announcement of the transaction can be found at http://www.cangenbio.com/mr5.html.  
 
The expanded collaboration includes funding from Olympus for a prospective clinical trial. Cangen has commenced patient recruitment and will manage the trial from its Asia Clinical Trial Center in Seoul, Korea.

Apatoff | Peters advised Cangen in its negotiation of the original collaborative research agreement with Olympus, as well as the agreement expanding the collaboration and funding the clinical study.

“This transaction is a major milestone for Cangen and will accelerate the commercialization of the company’s diagnostic test for the early detection of lung cancer,” said Adam Apatoff, Principal in Apatoff | Peters.  “Cangen is among the leading emerging companies in the I-270 biotechnology corridor and we congratulate the Company’s management team on its continuing success.”
 
Richard A. Silfen, President of Cangen noted, “As counsel, Apatoff | Peters coordinated negotiations and managed communications with Olympus to help us successfully navigate the complexity of the transaction.  The firm’s work on this and other complex corporate and commercial matters provides real value both as legal counsel and business advisors to our rapidly-growing company.”

Cangen Biotechnologies, Inc. is a cancer-focused biotechnology company developing non-invasive diagnostic tests for early detection of cancer, chemosensitivity technologies to enhance the selection of cancer therapeutic regimes, as well as targeted drug and biologic cancer therapies, including vaccines. The company is currently enrolling patients in a Phase 3 study to evaluate a molecular diagnostic test for the early detection of bladder cancer, based on microsatellite DNA instability.  Cangen Biotechnologies is headquartered in Bethesda, MD, has laboratories in Rockville, MD and conducts additional research at Johns Hopkins University in Baltimore, MD. The company has a clinical trial center in Seoul, Korea and operations in Tokyo, Japan.  Cangen is on the World Wide Web at http://www.cangenbio.com.
__________

Apatoff | Peters, LLC counsels clients on Technology, Tax, Corporate and Estate Planning matters.  The firm enables success for technology firms, growing businesses, established companies and individuals by putting clients first, balancing each client’s unique concerns with sound legal advice and business guidance.  In 2005, Apatoff | Peters was recognized as among the Top Washington Lawyers by the Washington Business Journal.  To learn how the firm can help you to see your path™ to success, visit the firm’s website, http://www.apatoffpeters.com.